Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.

Lin ShenJun GuoQingyuan ZhangHongming PanYing YuanYuxian BaiTianshu LiuQing ZhouJun ZhaoYongqian ShuXiaoming HuangSiyang WangJie WangAiping ZhouDingwei YeTing SunYujuan GaoSilu YangZoubai WangJian LiYi-Long Wu

Published in: Journal for immunotherapy of cancer (2021)

CTR20160872.

Keyphrases

open label
double blind
placebo controlled
clinical trial